Recombinant modified vaccinia virus ankara (mva) filovirus vaccine

A vaccine combination for generating a protective immune response against at least one filovirus subtype combination, the vaccine combination comprising:

• (a) a first composition comprising an immunologically effective amount of a MVA vector comprising a nucleic acid encoding antigenic proteins of at least two filovirus subtypes, together with a pharmaceutically acceptable carrier;
• and
• (b) a second composition comprising an immunologically effective amount of a MVA vector or a fowlpox vector comprising a nucleic acid encoding an antigenic protein of a first filovirus subtype, together with a pharmaceutically acceptable carrier;
• wherein one of the compositions is a priming composition and the other composition is a boosting composition.

A method of providing protective immunity or a protective immune response in a subject comprising administering to the subject:

• (a) a first composition comprising an immunologically effective amount of a MVA vector comprising a nucleic acid encoding antigenic proteins of at least two filovirus subtypes, together with a pharmaceutically acceptable carrier;
• and
• (b) a second composition comprising an immunologically effective amount of a MVA vector or a fowlpox vector comprising a nucleic acid encoding an antigenic protein of a first filovirus subtype, together with a pharmaceutically acceptable carrier;
• wherein one of the compositions is a priming composition and the other composition is a boosting composition.

A recombinant MVA vector comprising:

• a) SEQ ID NO:5, SEQ ID NO:19, and SEQ ID NO:30,
• b) SEQ ID NO:5, SEQ ID NO:19, SEQ ID NO:28, and SEQ ID NO:30;
• or
• c) SEQ ID NO:19 and SEQ ID NO:33.

A method for production of filovirus-like particles in a subject comprising administering to the subject:

• (a) an immunologically effective amount of a MVA vector comprising a nucleic acid encoding antigenic proteins of at least one filovirus glycoprotein and a filovirus virion protein 40 (VP40), together with a pharmaceutically acceptable carrier;
• and
• (b) an immunologically effective amount of a fowlpox vector or a MVA vector comprising a nucleic acid encoding an antigenic protein of a first filovirus subtype, together with a pharmaceutically acceptable carrier;
• wherein one of the vectors is a priming vaccine and the other vector is a boosting vaccine.